The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 05, 2023
Filed:
Feb. 09, 2018
Applicant:
Csl Behring Gmbh, Marburg, DE;
Inventors:
Assignee:
CSL Behring GmbH, Marburg, DE;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/36 (2006.01); A61P 7/02 (2006.01); A61K 31/727 (2006.01); A61K 38/38 (2006.01); A61K 38/48 (2006.01);
U.S. Cl.
CPC ...
A61K 38/36 (2013.01); A61K 31/727 (2013.01); A61K 38/385 (2013.01); A61K 38/4833 (2013.01); A61K 38/4846 (2013.01); A61P 7/02 (2018.01); C12Y 304/21005 (2013.01); C12Y 304/21021 (2013.01); C12Y 304/21022 (2013.01); C12Y 304/21038 (2013.01);
Abstract
The invention pertains to a blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings of patients having an acquired coagulation factor deficiency or for use in the treatment or prophylaxis of bleedings of patients having a congenital deficiency of a coagulation factor. Said product comprises at least isolated prothrombin (Factor II) and isolated Antithrombin III (ATIII), whereby the molar ratio between ATIII to Factor II is at least 1:30. By administration of said product the patient's risk for a thromboembolic complication is reduced.